DOCSLIB.ORG

Guidance for Reviewers Pharmacology/Toxicology Review Format

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidance for Reviewers Pharmacology/Toxicology Review Format Guidance for Reviewers Pharmacology/Toxicology Review Format U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Pharmacology/Toxicology May 2001 Guidance for Reviewers Pharmacology/Toxicology Review Format Additional copies are available from: Drug Information Branch (HFD-210) Center for Drug Evaluation and Research (CDER) 5600 Fishers Lane, Rockville, MD 20857, (Tel) 301-827-4570 Internet at http://www.fda.gov/der/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Pharmacology/Toxicology May 2001 Guidance for Reviewers Table of Contents I. INTRODUCTION ....................................................................................................1 II. BACKGROUND.......................................................................................................1 III. DISCUSSION ...........................................................................................................1 A. IND REVIEW FORMAT ....................................................................................1 B. NDA REVIEW FORMAT...................................................................................1 IV. ATTACHMENTS .....................................................................................................1 A. IND REVIEW FORMAT ....................................................................................A-i B. NDA REVIEW FORMAT...................................................................................B-i Guidance for Reviewers1 Pharmacology/Toxicology Review Format I. INTRODUCTION This document contains as attachments internal FDA review formats currently being used by pharmacology/toxicology reviewers in IND and NDA primary reviews. The attached format documents are being published to provide internal and external stakeholders with an understanding of the standard format and content of pharmacology/toxicology reviews. FDA uses the format documents for a number of reasons. First of all, standardization provides for unified communication amongst multiple audiences, including secondary reviewers, re-assigned reviewers, and ultimately the American public. Standardization also ensures that the most important information is captured in all reviews. In addition, the standard format makes it readily apparent what types of studies have and have not been reviewed, and assists other reviewers when reviews are referenced at later times. Reviewers use these formats for most original, supplemental, and amended applications. In some cases the formats may not be used, such as for safety studies or consults to other groups, where short response times restrict their use. These format documents are consistent with the ICH Common Technical Document (CTD) and will eventually be considered in the Center-wide Good Review Practices (GRP) initiative. II. DISCUSSION A. IND Review Format For IND reviews, the reviewer should use only the headers for which there is data. Thus, in the majority of IND reviews, many of the headers will not be used. B. NDA Review Format For NDA reviews, the reviewer should use all the headers, including those for which there are no data. If there are no data, a note will be made that data were not submitted. Thus, for NDA reviews, all of the headers will be listed, with a brief note following the headers for which there are no data. 1 This guidance has been prepared by the Associate Director for Pharmacology and Toxicology, Office of Review Management in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). This guidance document represents the Agency’s current format used for pharmacology/toxicology reviews. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes, regulations, or both. 1 III. ATTACHMENTS A. IND Review Format B. NDA Review Format 2 ATTACHMENT A: IND REVIEW FORMAT PHARMACOLOGY/TOXICOLOGY IND number: Review number: Sequence number/date/type of submission: Information to sponsor: Yes ( ) No ( ) Sponsor and/or agent: Manufacturer for drug substance : Reviewer name: Division name: HFD #: Review completion date: Drug: Trade name: Generic name (list alphabetically): Code name: Chemical name: CAS registry number: Mole file number: Molecular formula/molecular weight: Structure: Relevant INDs/NDAs/DMFs: Drug class: Indication: Clinical formulation: Route of administration: Proposed clinical protocol: Previous clinical experience: Disclaimer: Tabular and graphical information is from sponsor’s submission unless stated otherwise. A-i OVERALL SUMMARY AND EVALUATION: Introduction: Safety evaluation: Safety issues relevant to clinical use: Other clinically relevant issues: Conclusions: Communication review: Investigator’s brochure/informed consent review: RECOMMENDATIONS: Internal comments: External recommendations (to sponsor): Draft letter content for sponsor (if not same as above): Future development issues: Reviewer signature: Team leader signature [concurrence/non-concurrence]: cc: list: Memorandum of non-concurrence (if appropriate, attached): Addendum to review (if necessary): A-ii Studies reviewed within this submission: Studies not reviewed within this submission: Introduction and drug history: A-iii TABLE OF CONTENTS PHARMACOLOGY:...................................................................................................................A-1 SAFETY PHARMACOLOGY:...................................................................................................A-1 PHARMACOKINETICS/TOXICOKINETICS:..........................................................................A-2 TOXICOLOGY:..........................................................................................................................A-3 Histopathology Inventory for IND # .........................................................................................A-4 GENETIC TOXICOLOGY:.........................................................................................................A-7 CARCINOGENICITY:................................................................................................................A-9 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY:..............................................A-11 SPECIAL TOXICOLOGY STUDIES:.......................................................................................A-13 APPENDIX/ATTACHMENTS:.................................................................................................A-14 A-iv Reviewer: IND No. PHARMACOLOGY: Primary pharmacodynamics: Mechanism of action: Drug activity related to proposed indication: Secondary pharmacodynamics: Pharmacology summary: Pharmacology conclusions: SAFETY PHARMACOLOGY: Neurological effects: Cardiovascular effects: Pulmonary effects: Renal effects: Gastrointestinal effects: Abuse liability: Other: Safety pharmacology summary: Safety pharmacology conclusions: A-1 Reviewer: IND No. PHARMACOKINETICS/TOXICOKINETICS: PK parameters: Absorption: Distribution: Metabolism: Excretion: Other studies: PK/TK summary: PK/TK conclusions: A-2 Reviewer: IND No. TOXICOLOGY: Study title: Key study findings: Study no: Volume #, and page #: Conducting laboratory and location: Date of study initiation: GLP compliance: QA report: yes ( ) no ( ) Drug, lot #, radiolabel, and % purity: Formulation/vehicle: Methods (unique aspects): Dosing: Species/strain: #/sex/group or time point (main study): Satellite groups used for toxicokinetics or recovery: Age: Weight: Doses in administered units: Route, form, volume, and infusion rate: Observations and times: Clinical signs: Body weights: Food consumption: Ophthalmoscopy: EKG: Hematology: Clinical chemistry: Urinalysis: Gross pathology: Organs weighed: Histopathology: Toxicokinetics: Other: Results: Mortality: Clinical signs: Body weights: A-3 Reviewer: IND No. Food consumption: Ophthalmoscopy: Electrocardiography: Hematology: Clinical chemistry: Urinalysis: Organ weights: Gross pathology: Histopathology: Toxicokinetics: Summary of individual study findings: Toxicology summary: Toxicology conclusions: Histopathology Inventory for IND # Study Species Adrenals Aorta Bone Marrow smear Bone (femur) Brain Cecum Cervix Colon Duodenum Epididymis Esophagus Eye Fallopian tube Gall bladder Gross lesions Harderian gland Heart Ileum Injection site Jejunum A-4 Reviewer: IND No. Kidneys Lachrymal gland Larynx Liver Lungs Lymph nodes, cervical Lymph nodes mandibular Lymph nodes, mesenteric Mammary Gland Nasal cavity Optic nerves Ovaries Pancreas Parathyroid Peripheral nerve Pharynx Pituitary Prostate Rectum Salivary gland Sciatic nerve Seminal vesicles Skeletal muscle Skin Spinal cord Spleen Sternum Stomach Testes Thymus Thyroid Tongue Trachea Urinary bladder Uterus Vagina Zymbal gland Standard List A-5 Reviewer: IND No. X, histopathology performed *, organ weight obtained A-6 Reviewer: IND No. GENETIC TOXICOLOGY: Study title: Key findings: Study no: Study type (if not reflected in title): Volume #, and page #: Conducting laboratory and location: Date of study initiation: GLP compliance: QA reports: yes ( ) no ( ) Drug, lot #, radiolabel, and % purity: Formulation/vehicle: Methods: Strains/species/cell line: Dose selection criteria: Basis of dose selection: Range finding studies: Test agent stability: Metabolic activation system: Controls: Vehicle: Negative
Load more

Recommended publications
  • Pharmacology
    Pharmacology New for 2020-2021 Competitor orientation deleted from ILC. Event Summary Pharmacology provides HOSA members with the opportunity to gain knowledge and skills regarding the area of healthcare concerned with uses, effects, and modes of actions of drugs. This competitive event consists of a written test with a tie-breaker essay question. This event aims to inspire members to learn about how drugs work in the body, proper administration, and adaptations for different patients and conditions. Dress Code Competitors must be in official HOSA uniform or proper business attire. Bonus points will be awarded for proper dress. General Rules 1. Competitors in this event must be active members of HOSA-Future Health Professionals, in good standing. 2. Secondary and Postsecondary/Collegiate divisions are eligible to compete in this event. 3. Competitors must be familiar with and adhere to the “General Rules and Regulations of the HOSA Competitive Events Program (GRR)." 4. All competitors shall report to the site of the event at the time designated for each round of competition. At ILC, competitor’s photo ID must be presented prior to ALL competition rounds. Official References • Fulcher, Soto and Fulcher. Pharmacology: Principles and Applications. Elsevier, Latest edition. • Ford, Susan and Sally Roach. Roach’s Introductory Clinical Pharmacology. Wolters Kluwer, Latest edition. Written Test 5. Test Instructions: The written test will consist of 100 multiple choice items in a maximum of 90 minutes. 6. Time Remaining Announcements: There will be a verbal announcement when there are 60 minutes, 30 minutes, 15 minutes, 5 minutes, and 1 minute remaining to complete the test.
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St
    2014;22(1):13-18 TCP Translational and Clinical Pharmacology http://dx.doi.org/10.12793/tcp.2014.22.1.13 Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, Korea *Correspondence: S. Han; Tel: +82-2-2258-7326, Fax: +82-2-2258-7876, E-mail: [email protected] Received 31 May 2014 Primary health care providers play a critical role in maintaining public health, and the appropri- Accepted 31 May 2014 ate use of pharmaceutical products is one of the major parts of their practice. This series of articles, pISSN: 2289-0882 entitled ‘Clinical Pharmacology Review for Primary Health Care Providers,’ is intended to help pri- mary health care providers select more appropriate prescriptions for frequently used drugs based on up-to-date information. We expect that this effort will contribute to improvements in public health and diminish unnecessary drug use. Introduction tion on the H1 receptor.[8] THERAPEU Antihistamines include some of the most frequently prescribed drugs in the primary health care environment for the symp- Generations and Classes tomatic relief of allergic diseases, the common cold, urticaria, Many primary health care providers are well-informed about T and insomnia.[1-5] The importance of antihistamines has been the different ‘generations’ of antihistamines but not about the ICS TU emphasized as the prevalence of target diseases increases.[6,7] different ‘classes’ characterized according to chemical structure. However, the appropriate use, clinical effectiveness, and target [1] This discrepancy seems reasonable because ‘inter-generation’ T populations for prescription of antihistamines are still a matter differences are more prominent than ‘inter-class’ differences.
    [Show full text]
  • Department of Pharmacology (GRAD) 1
    Department of Pharmacology (GRAD) 1 faculty participate fully at all levels. The department has the highest DEPARTMENT OF level of NIH funding of all pharmacology departments and a great diversity of research areas is available to trainees. These areas PHARMACOLOGY (GRAD) include cell surface receptors, G proteins, protein kinases, and signal transduction mechanisms; neuropharmacology; nucleic acids, cancer, Contact Information and antimicrobial pharmacology; and experimental therapeutics. Cell and molecular approaches are particularly strong, but systems-level research Department of Pharmacology such as behavioral pharmacology and analysis of knock-in and knock-out Visit Program Website (http://www.med.unc.edu/pharm/) mice is also well-represented. Excellent physical facilities are available for all research areas. Henrik Dohlman, Chair Students completing the training program will have acquired basic The Department of Pharmacology offers a program of study that leads knowledge of pharmacology and related fields, in-depth knowledge in to the degree of doctor of philosophy in pharmacology. The curriculum is their dissertation research area, the ability to evaluate scientific literature, individualized in recognition of the diverse backgrounds and interests of mastery of a variety of laboratory procedures, skill in planning and students and the broad scope of the discipline of pharmacology. executing an important research project in pharmacology, and the ability The department offers a variety of research areas including to communicate results, analysis, and interpretation. These skills provide a sound basis for successful scientific careers in academia, government, 1. Receptors and signal transduction or industry. 2. Ion channels To apply to BBSP, students must use The Graduate School's online 3.
    [Show full text]
  • Pharmacology 101
    Pharmacology 101 Tyler Fischback, PharmD, BCPS, DPLA Clinical Pharmacy Manager Confluence Health Wenatchee, WA Objectives • Define Pharmacology, Pharmacokinetics and Pharmacodynamics • Understand how drug interactions work • Understand how some specific drugs behave in the body (opioids, benzodiazepines, amiodarone) • Apply pharmacology principles into practice Medication Errors and Adverse Drug Events • Error: An error of commission or omission at any step along the pathway that begins when a clinician prescribes a medication and ends when the patient actually received the medication. • ADE: Harm experienced by a patient as a result of exposure to a medication. ADE does not necessarily indicate an error or poor care. However, ~1/2 of ADEs are preventable. Anyone here ever seen a medication error or adverse drug event? Anyone here ever made a medication error? How many different prescription medications are available on the U.S. market? 1,000 So, it’s no surprise why we see so many problems………………… EXCEPT……. The real number is 10,000 Adverse Drug Events • ~1/3 of U.S. adults use 5 or more medications • Annually, ADE = 700,000 ER visits and 100,000 hospitalizations • So, is pharmacology important to your work? • Additionally, 5% of hospitalized patient experience an ADE during their stay • High risk: Anticoagulants, Opioids, Insulin, Cardiac, and Transitions of Care Adverse Drug Events, cont. • Elderly are more susceptible • Pediatrics patients more susceptible (weight-based dosing), especially liquids • Caregivers and patients admittedly
    [Show full text]
  • Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations
    International Journal of Molecular Sciences Editorial Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations Giuliano Ciarimboli Experimental Nephrology, Department of Internal Medicine D, University Hospital Münster, 48149 Münster, Germany; [email protected] This editorial summarizes the 13 scientific papers published in the Special Issue “Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations” of the International Journal of Molecular Sciences. In this Special Issue, the readers will find integrative information on transporters for organic cations. Besides reviews on physi- ology, pharmacology, and toxicology of these transporters [1–3], which offer a concise overview of the field, the readers will find original research work focusing on specific transporter aspects. Specifically, the review “Organic Cation Transporters in Human Physiology, Phar- macology, and Toxicology” by Samodelov et al. [1] summarizes well the general as- pects of physiology, pharmacology, and toxicology of transporter for organic cations. The other review “Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts” by Ali Selo et al. [2] focuses on these aspects of transporters for organic cations in the lung, an important but often ne- glected field. In the paper “Systems Biology Analysis Reveals Eight SLC22 Transporter Subgroups, Including OATs, OCTs, and OCTNs”, by performing a system biology analysis of SLC22 transporters, Engelhart et al. [4] suggest the existence of a transporter–metabolite network. They propose that, in this network, mono-, oligo-, and multi-specific SLC22 transporters Citation: Ciarimboli, G. Physiology, interact to regulate concentrations and fluxes of many metabolites and signaling molecules. Biochemistry, and Pharmacology of In particular, the organic cation transporters (OCT) subgroup seems to be associated with Transporters for Organic Cations.
    [Show full text]
  • 110499 Calcium-Antagonist Drugs
    DRUG THERAPY Review Article Drug Therapy smooth muscle (arteriolar and venous), nonvascular smooth muscle (bronchial, gastrointestinal, genitouri- nary, and uterine), and noncontractile tissues (pan- A LASTAIR J.J. WOOD, M.D., Editor creas, pituitary, adrenal glands, salivary glands, gastric mucosa, white cells, platelets, and lacrimal tissue). Blockade of L-type channels in vascular tissues results CALCIUM-ANTAGONIST DRUGS in the relaxation of vascular smooth muscle and in cardiac tisssue results in a negative inotropic effect. DARRELL R. ABERNETHY, M.D., PH.D., The ability of these drugs to decrease smooth-muscle AND JANICE B. SCHWARTZ, M.D. and myocardial contractility results in both clinically desirable antihypertensive and antianginal effects and undesirable myocardial depression. RUGS classified as calcium antagonists or Other calcium channels with electrophysiologic calcium-channel blockers were introduced properties have also been identified. These channels, into clinical medicine in the 1960s and are to which the calcium antagonists do not bind, in- D clude the N-type channels in neuronal tissue, P-type now among the most frequently prescribed drugs for the treatment of cardiovascular diseases.1 Although channels in Purkinje tissues, and T-type (transient potential) channels in cardiac nodal structures and the currently available calcium antagonists are chem- 4,5 ically diverse, they share the common property of vascular smooth muscle. blocking the transmembrane flow of calcium ions Regulation of the L-type channels may differ in through voltage-gated L-type (slowly inactivating) different types of cells. In cardiac myocytes, these channels.2 These drugs have proved effective in pa- channels are activated by catecholamines and other stimuli that activate adenylyl cyclase or cyclic aden- tients with hypertension, angina pectoris, and cardi- 6-8 ac arrhythmias and may be beneficial in patients with osine monophosphate–dependent protein kinase.
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]
  • Calcium Channel Blockers in Cardiovascular Pharmacotherapy
    Cardiovascular Pharmacology Core Review Journal of Cardiovascular Pharmacology and Therapeutics 2014, Vol. 19(6) 501-515 Calcium Channel Blockers in ª The Author(s) 2014 Reprints and permission: Cardiovascular Pharmacotherapy sagepub.com/journalsPermissions.nav DOI: 10.1177/1074248414530508 cpt.sagepub.com Theophile Godfraind1 Abstract This paper summarizes the pharmacological properties of calcium channel blockers (CCBs), their established therapeutic uses for cardiovascular disorders and the current improvement of their clinical effects through drug combinations. Their identification resulted from study of small molecules including coronary dilators, which were named calcium antagonists. Further experiments showed that they reduced contraction of arteries by inhibiting calcium entry and by interacting with binding sites identified on voltage-dependent calcium channels. This led to the denomination calcium channel blockers. In short-term studies, by decreasing total peripheral resistance, CCBs lower arterial pressure. By unloading the heart and increasing coronary blood flow, CCBs improve myocardial oxygenation. In long-term treatment, the decrease in blood pressure is more pronounced in hypertensive than in normotensive patients. A controversy on the safety of CCBs ended after a large antihypertensive trial (ALLHAT) sponsored by the National Heart, Lung, and Blood Institute. There are two main types of CCBs: dihydopyridine and non-dihydropyridine; the first type is vascular selective. Dihydropyrines are indicated for hypertension, chronic, stable and vasospastic angina. Non-dihydropyridines have the same indications plus antiarrythmic effects in atrial fibrillation or flutter and paroxysmal supraventricular tachycardia. In addition, CCBs reduced newly formed coronary lesions in atherosclerosis. In order to reach recommended blood pressure goals, there is a recent therapeutic move by combination of CCBs with other antihypertensive agents particularly with inhibitors acting at the level of the renin-angiotensin system.
    [Show full text]
  • PHAR 3102 Molecular Pharmacology COURSE OUTLINE
    FACULTY OF MEDICINE SCHOOL OF MEDICAL SCIENCES DEPARTMENT OF PHARMACOLOGY PHAR 3102 Molecular Pharmacology COURSE OUTLINE SEMESTER 1, 2013 CONTENTS PAGE PHAR3102 COURSE INFORMATION ......................................................................... 1 Objectives of the course ............................................................................................ 1 Course co-ordinator and lecturers: ............................................................................ 1 Course structure and teaching strategies .................................................................. 1 Approach to learning and teaching ............................................................................ 2 Student learning outcomes ....................................................................................... 2 Assessment procedures ............................................................................................ 2 Textbooks and other resources ................................................................................. 3 Course evaluation and development ......................................................................... 3 GENERAL INFORMATION .......................................................................................... 4 Official communication by email ................................................................................ 4 Attendance requirements .......................................................................................... 5 Behaviour in practical classes ..................................................................................
    [Show full text]
  • Calcium Channel Blockers
    Calcium Channel Blockers Summary In general, calcium channel blockers (CCBs) are used most often for the management of hypertension and angina. There are 2 classes of CCBs: the dihydropyridines (DHPs), which have greater selectivity for vascular smooth muscle cells than for cardiac myocytes, and the non-DHPs, which have greater selectivity for cardiac myocytes and are used for cardiac arrhythmias. The DHPs cause peripheral edema, headaches, and postural hypotension most commonly, all of which are due to the peripheral vasodilatory effects of the drugs in this class of CCBs. The non-DHPs are negative inotropes and chronotropes; they can cause bradycardia and depress AV node conduction, increasing the risk of heart failure exacerbation, bradycardia, and AV block. Clevidipine is a DHP calcium channel blocker administered via continuous IV infusion and used for rapid blood pressure reductions. All CCBs are substrates of CYP3A4, but both diltiazem and verapamil are also inhibitors of 3A4 and have an increased risk of drug interactions. Verapamil also inhibits CYP2C9, CYP2C19, and CYP1A2. Pharmacology CCBs selectively inhibit the voltage-gated L-type calcium channels on cardiac myocytes, vascular smooth muscle cells, and cells within the sinoatrial (SA) and atrioventricular (AV) nodes, preventing influx of extracellular calcium. CCBs act by either deforming the channels, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the major cellular calcium store, the endoplasmic reticulum. Calcium influx via these channels serves for excitation-contraction coupling and electrical discharge in the heart and vasculature. A decrease in intracellular calcium will result in inhibition of the contractile process of the myocardial smooth muscle cells, resulting in dilation of the coronary and peripheral arterial vasculature.
    [Show full text]
  • The Uniform System of Classification (USC)
    The Uniform System of Classification (USC) Purpose The Uniform System of Classification (USC) is a therapeutic classification system created by IQVIA America and the Pharmaceutical Marketing Research Group to resolve a need for therapeutic classification of pharmaceutical products. This system is market-oriented and is unique to North America (the United States and Canada) and is the standard for pharmaceutical product classification. The only pharmaceutical categorization system that rivals the USC is the Anatomical Classification system (ATC), used outside the United States and Canada. The USC provides logical groupings of pharmaceutical products considered to compete in the same or similar markets; each category provides the manufacturer a solution to determine the market share for their product(s), as well as their competitors. This type of classification creates market shares showing movement and changes in a given area resulting from new product launches and competing products. Structure The USC is a five-digit, hierarchical, classification system. The USC 2 level, ranging from 01 to 99, can accommodate ninety-nine unique categories. The subsequent levels accommodate nine unique subcategories. The USC 3 level consists of the detail from level two in addition to any detail associated with level three; the range is limited to nine unique subcategories The USC 4 level consists of the detail from level two, three and four. This level typically will carry the chemical structure, indication, or method of action. The USC 5 level provides the most granular detail. This level consists of the detail strung from levels two, three and four. 1 Example of USC structure Process The USC is a proprietary product, belonging exclusively to IQVIA; although a client may request a new USC class or the reclassification of a product, IQVIA is solely accountable for the appropriate classification of all drugs and for the approval/denial of all drug reclassifications.
    [Show full text]